Home » Stocks » DRRX

DURECT Corporation (DRRX)

Stock Price: $1.76 USD 0.04 (2.33%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.75 -0.01 (-0.57%) May 7, 5:29 PM
Market Cap 399.48M
Revenue (ttm) 29.55M
Net Income (ttm) -768,000
Shares Out 217.54M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.76
Previous Close $1.72
Change ($) 0.04
Change (%) 2.33%
Day's Open 1.72
Day's Range 1.72 - 1.78
Day's Volume 351,572
52-Week Range 1.52 - 2.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

Shares of Durect (NASDAQ:DRRX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed ...

3 days ago - Benzinga

CUPERTINO, Calif., May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update.

3 days ago - PRNewsWire

Reddit penny stocks to watch as May 2021 gets kicked off The post Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now appeared first on Penny Stocks to Buy, Picks, News and Information ...

Other stocks mentioned: ATOS, SOS
5 days ago - PennyStocks

CUPERTINO, Calif., April 27, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the mark...

1 week ago - PRNewsWire

CUPERTINO, Calif., March 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed research paper describing the binding sites and proposed mechanism o...

1 month ago - PRNewsWire

Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate ...

2 months ago - Benzinga

CUPERTINO, Calif., March 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provided a corporate update...

2 months ago - PRNewsWire

CUPERTINO, Calif., March 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021. All conferen...

2 months ago - PRNewsWire

CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver ...

3 months ago - PRNewsWire

CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver ...

3 months ago - PRNewsWire

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certai...

3 months ago - Market Watch

CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for infilt...

3 months ago - PRNewsWire

Investors who target growth could be interested in the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year b...

Other stocks mentioned: HONE, INSW
3 months ago - GuruFocus

CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on De...

4 months ago - PRNewsWire

CUPERTINO, Calif., Dec. 7, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a...

5 months ago - PRNewsWire

CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic...

5 months ago - PRNewsWire

DURECT Corporation (DRRX) CEO Jim Brown on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases,...

6 months ago - PRNewsWire

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, CWBR, GRFS, PTI
6 months ago - Zacks Investment Research

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Development," ta...

6 months ago - PRNewsWire

Durect (DRRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, ...

7 months ago - PRNewsWire

CUPERTINO, Calif., Aug. 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E.

8 months ago - PRNewsWire

As we head further into August, a handful of penny stocks look like good opportunities. That said, here's seven penny stocks to buy.

Other stocks mentioned: SKYS, NGD, PRTY, SEAC, UMC, ZSAN
8 months ago - InvestorPlace

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Durect (DRRX) delivered earnings and revenue surprises of 75.00% and 30.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CUPERTINO, Calif., Aug. 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2020 and provided a corporate update.

9 months ago - PRNewsWire

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Other stocks mentioned: NLTX, RLMD
10 months ago - The Motley Fool

CUPERTINO, Calif., June 26, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is...

10 months ago - PRNewsWire

DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ Injury

11 months ago - Seeking Alpha

The biotech becomes a COVID-19 play and benefits from a competitor's failure.

11 months ago - The Motley Fool

DURECT Corp (DRRX) CEO James Brown on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -41.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Durect Is A Biotech To Watch With Key Catalysts In 2020

1 year ago - Seeking Alpha

DURECT Corporation (DRRX) CEO Jim Brown on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

Other stocks mentioned: MTNB, NOG, TAST, VBIV
1 year ago - InvestorPlace

Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: LLY, HSDT
1 year ago - Seeking Alpha

Durect Corp. (NASDAQ: DRRX) shares dropped early on Friday after the U.S. Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) announced its vote on Posimir, t...

1 year ago - 24/7 Wall Street

Biopharmaceutical company Durect Corp. DRRX, +3.25% said Friday a U.S. Food and Drug Administration committee ended a meeting to review its Posimir treatment for post-surgical pain with a split vote, as...

1 year ago - Market Watch

Shares of biopharmaceutical company Durect Corp. DRRX, +3.25% were halted Thursday, ahead of a U.S.

1 year ago - Market Watch

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, EVER, ISEE, KOD, PRVB ...
1 year ago - The Motley Fool

The biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.

1 year ago - The Motley Fool

Shares of Durect Corp. DRRX, -29.64% tumbled 34% on Thursday morning after the biopharmaceutical company said it would stop development of DUR-928 as a treatment for psoriasis.

1 year ago - Market Watch

Investors jump in ahead of a binary event.

1 year ago - The Motley Fool

DURECT Corp (DRRX) CEO James Brown on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Sep 28, 2000
CEO
James Brown
Employees
81
Stock Exchange
NASDAQ
Ticker Symbol
DRRX
Full Company Profile

Financial Performance

In 2020, DRRX's revenue was $30.11 million, an increase of 20.09% compared to the previous year's $25.07 million. Losses were -$582,000, -97.17% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for DRRX stock is "Strong Buy." The 12-month stock price forecast is 6.67, which is an increase of 278.98% from the latest price.

Price Target
$6.67
(278.98% upside)
Analyst Consensus: Strong Buy